A total of @ patients were randomly divided into a combination group ( pemetrexed + bevacizumab , n = @ ) and a pemetrexed group ( n = @ ) and assessed for disease control ( CR+PR+SD ) after @-cycles of first-line GP chemotherapy ( gemcitabine + cisplatin ) .